Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Neutropenia 1

Interventions

Filgrastim 5Docetaxel 3Carboplatin 3Cyclosporine 2Cyclophosphamide 2sargramostim 1pegfilgrastim 1ixabepilone 1flt3 ligand protein 1eflapegrastim 1Topotecan 1Thrombopoietin 1Taxes 1Stem Cell Factor 1Phenobarbital 1Paclitaxel 1Oxaliplatin 1Mannose-Binding Lectin 1Leucovorin 1Lenalidomide 1Irinotecan 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Etoposide 1Epoetin Alfa 1Epirubicin 1EC regimen 1Doxorubicin 1Diet, High-Fat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neutropenia × eflapegrastim × Clear all
NCT04187898 2024-09-19

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Spectrum Pharmaceuticals, Inc

Phase 1 Completed
59 enrolled
Breast

Breast Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡